UY37961A - Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) - Google Patents

Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)

Info

Publication number
UY37961A
UY37961A UY0001037961A UY37961A UY37961A UY 37961 A UY37961 A UY 37961A UY 0001037961 A UY0001037961 A UY 0001037961A UY 37961 A UY37961 A UY 37961A UY 37961 A UY37961 A UY 37961A
Authority
UY
Uruguay
Prior art keywords
new
carboxamids
pirazolo
indolo
vhb
Prior art date
Application number
UY0001037961A
Other languages
English (en)
Inventor
Alastair Donald Dr
Jasper Springer Dr
Andreas Urban Dr
Susanne Bonsmann
Anita Wegert Dr
Original Assignee
Aicuris Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aicuris Gmbh & Co Kg filed Critical Aicuris Gmbh & Co Kg
Publication of UY37961A publication Critical patent/UY37961A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere, en general, a nuevos agentes antivíricos. Específicamente, la presente invención se refiere a compuestos que pueden inhibir la proteína o proteínas codificada(s) por el virus de la hepatitis B (VHB) o interferir con la función del ciclo de replicación del VHB, a composiciones que comprenden estos compuestos, a métodos para inhibir la replicación del virus VHB, a métodos para tratar o prevenir la infección por VHB y a procesos o intermedios para fabricar los compuestos.
UY0001037961A 2017-11-02 2018-11-05 Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb) UY37961A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17199676 2017-11-02

Publications (1)

Publication Number Publication Date
UY37961A true UY37961A (es) 2019-05-31

Family

ID=60201937

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037961A UY37961A (es) 2017-11-02 2018-11-05 Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)

Country Status (22)

Country Link
US (1) US11236087B2 (es)
EP (1) EP3704119A1 (es)
JP (1) JP2021501768A (es)
KR (1) KR20200083552A (es)
CN (1) CN111527087A (es)
AR (1) AR115131A1 (es)
AU (1) AU2018361365C1 (es)
BR (1) BR112020008765A2 (es)
CA (1) CA3081399A1 (es)
CL (1) CL2020001146A1 (es)
CU (1) CU20200045A7 (es)
EA (1) EA202091114A1 (es)
EC (1) ECSP20029569A (es)
GE (1) GEP20227374B (es)
IL (1) IL274297A (es)
MA (1) MA50520A (es)
MX (1) MX2020004838A (es)
PH (1) PH12020550531A1 (es)
SG (1) SG11202003746UA (es)
TW (1) TW201925199A (es)
UY (1) UY37961A (es)
WO (1) WO2019086142A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091113A1 (ru) * 2017-11-02 2020-08-28 Айкурис Гмбх Унд Ко. Кг Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
UY38434A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
UY38436A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
UY38437A (es) * 2018-11-02 2020-05-29 Aicuris Gmbh & Co Kg Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
WO2020113077A1 (en) * 2018-11-29 2020-06-04 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation
CU20210088A7 (es) * 2019-04-30 2022-06-06 Aicuris Gmbh & Co Kg Compuestos derivados sustituidos de indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
EP3962913A1 (en) * 2019-04-30 2022-03-09 AiCuris GmbH & Co. KG Novel indolizine-2-carboxamides active against the hepatitis b virus (hbv)
CA3139365A1 (en) 2019-06-06 2020-12-10 Aligos Therapeutics, Inc. Heterocyclic compounds
TW202138363A (zh) 2019-12-20 2021-10-16 德商拜耳廠股份有限公司 經取代之噻吩甲醯胺及其衍生物（三）
CA3202764A1 (en) 2020-11-23 2022-05-27 Enanta Pharmaceuticals, Inc. Novel spiropyrrolidine derived antiviral agents
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023107419A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023137007A1 (en) 2022-01-11 2023-07-20 Enanta Pharmaceuticals, Inc. Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19817264A1 (de) 1998-04-18 1999-10-21 Bayer Ag Neue Dihydropyrimidine
WO2000058302A1 (de) 1999-03-25 2000-10-05 Bayer Aktiengesellschaft Dihydropyrimidine und ihre verwendung zur behandlung von hepatitis b
AU3009801A (en) 1999-12-22 2001-07-03 Bayer Aktiengesellschaft Combinations of medicaments for treating viral diseases
DE10012823A1 (de) 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DK1320531T3 (da) 2000-08-10 2011-01-03 Pfizer Italia Srl Bicyclo-pyrazoler, der er aktive som kinase inhibitorer, fremgangsmåde til fremstilling deraf og farmaceutiske sammensætninger, der indeholder disse
CA2518395A1 (en) 2003-03-11 2004-09-23 Pharmacia Italia S.P.A. Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2006033995A2 (en) 2004-09-16 2006-03-30 Valeant Research And Development Thiazolidin-4-ones having anti-hepatitis b activity
EP1863483A4 (en) 2005-03-31 2010-03-31 Janssen Pharmaceutica Nv Bicyclic pyrazole compounds as anti-bacteriostatic agents
CA2619462A1 (en) 2005-08-16 2007-02-22 Amgen, Inc. Phosphodiesterase 10 inhibitors
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
JP5730896B2 (ja) 2009-12-04 2015-06-10 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ トリシクロピラゾール誘導体
WO2012114252A1 (en) * 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
EP3085368A1 (en) 2011-07-01 2016-10-26 Baruch S. Blumberg Institute Sulfamoylbenzamide derivatives as antiviral agents against hbv infection
US8629274B2 (en) 2011-12-21 2014-01-14 Novira Therapeutics, Inc. Hepatitis B antiviral agents
CN104302626B (zh) 2012-01-06 2016-09-07 爱尔兰詹森科学公司 4,4-二取代的-1,4-二氢嘧啶及其作为治疗乙型肝炎的药物的用途
PT2890683T (pt) 2012-08-28 2017-01-17 Janssen Sciences Ireland Uc Derivados de sulfamoílo bicíclicos fundidos e a sua utilização como medicamentos para o tratamento da hepatite b
TW201920090A (zh) 2012-08-28 2019-06-01 愛爾蘭商健生科學愛爾蘭無限公司 胺磺醯基－芳醯胺類及其做為治療ｂ型肝炎之醫藥劑的用途
US8993771B2 (en) 2013-03-12 2015-03-31 Novira Therapeutics, Inc. Hepatitis B antiviral agents
AU2014267198A1 (en) 2013-05-17 2015-11-05 F. Hoffmann-La Roche Ag 6-bridged heteroaryldihydropyrimidines for the treatment and prophylaxis of Hepatitis B virus infection
PT2997019T (pt) 2013-05-17 2018-11-21 Janssen Sciences Ireland Uc Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b
WO2015011281A1 (en) 2013-07-25 2015-01-29 Janssen R&D Ireland Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
CN105828823B (zh) 2013-10-18 2019-06-14 美国印第安纳大学研究和技术公司 乙型肝炎病毒组装效应物
CN106255684B (zh) 2013-11-14 2019-08-23 诺维拉治疗公司 氮杂环庚烷衍生物和治疗乙型肝炎感染的方法
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
CR20160337A (es) 2014-03-07 2016-09-20 Hoffmann La Roche Nuevas heteroarildihidropirimidinas 6-fusionadas para el tratamiento y la profilaxis de la infección por virus de la hepatitis b
CN110437153A (zh) 2014-03-13 2019-11-12 美国印第安纳大学研究和技术公司 乙型肝炎核心蛋白变构调节剂
MY196243A (en) 2014-03-28 2023-03-24 Sunshine Lake Pharma Co Ltd Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
WO2015172128A1 (en) 2014-05-09 2015-11-12 Indiana University Research And Technology Corporation Methods and compositions for treating hepatitis b virus infections
US20150375115A1 (en) 2014-06-30 2015-12-31 Microsoft Corporation Interacting with a story through physical pieces
RU2664329C1 (ru) 2014-08-14 2018-08-16 Ф. Хоффманн-Ля Рош Аг Новые пиридазоны и триазиноны для лечения и профилактики заражения вирусом гепатита b
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
AU2015358561A1 (en) 2014-12-02 2017-06-08 Novira Therapeutics, Inc. Sulfide alkyl and pyridyl reverse sulfonamide compounds for HBV treatment
US9550779B2 (en) 2014-12-30 2017-01-24 Novira Therapeutics, Inc. Derivatives and methods of treating hepatitis B infections
MA41338B1 (fr) 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
MX370769B (es) 2015-03-16 2019-12-20 Hoffmann La Roche Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
US10442788B2 (en) 2015-04-01 2019-10-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
WO2016177655A1 (en) 2015-05-04 2016-11-10 F. Hoffmann-La Roche Ag Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
US10738035B2 (en) 2015-05-13 2020-08-11 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
US10179131B2 (en) 2015-07-13 2019-01-15 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017015451A1 (en) 2015-07-22 2017-01-26 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
TWI786639B (zh) 2015-09-15 2022-12-11 美商艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017059059A1 (en) 2015-09-29 2017-04-06 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
EP3372606B1 (en) 2015-11-04 2020-04-08 Qilu Pharmaceutical Co., Ltd Crystal form, preparation method and intermediate of dihydropyrido ring compound
WO2017136403A1 (en) 2016-02-02 2017-08-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3426245B1 (en) 2016-03-07 2022-12-14 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN109153682B (zh) 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
EP3484885B1 (en) 2016-07-14 2020-03-04 H. Hoffnabb-La Roche Ag Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JP7051804B2 (ja) 2016-07-14 2022-04-11 エフ．ホフマン－ラ ロシュ アーゲー 感染症の治療のための６，７－ジヒドロ－４Ｈ－ピラゾロ［１，５－ａ］ピラジン化合物と６，７－ジヒドロ－４Ｈ－トリアゾロ［１，５－ａ］ピラジン化合物
WO2018011160A1 (en) 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018052967A1 (en) 2016-09-13 2018-03-22 Arbutus Biopharma, Inc. Substituted chromane-8-carboxamide compounds and analogues thereof, and methods using same
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
KR20190126102A (ko) 2017-03-02 2019-11-08 어셈블리 바이오사이언시스, 인크. 시클릭 술파미드 화합물 및 그의 사용 방법
US11098010B2 (en) 2017-03-21 2021-08-24 Arbutus Biopharma Corporation Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same

Also Published As

Publication number Publication date
AU2018361365B2 (en) 2021-04-01
CL2020001146A1 (es) 2020-10-09
CN111527087A (zh) 2020-08-11
CU20200045A7 (es) 2021-03-11
US20210179608A1 (en) 2021-06-17
BR112020008765A2 (pt) 2020-10-20
EA202091114A1 (ru) 2020-07-24
ECSP20029569A (es) 2020-07-31
AU2018361365A1 (en) 2020-05-21
MA50520A (fr) 2020-09-09
IL274297A (en) 2020-06-30
WO2019086142A1 (en) 2019-05-09
CA3081399A1 (en) 2019-05-09
US11236087B2 (en) 2022-02-01
PH12020550531A1 (en) 2021-03-22
MX2020004838A (es) 2020-10-16
SG11202003746UA (en) 2020-05-28
KR20200083552A (ko) 2020-07-08
AR115131A1 (es) 2020-12-02
EP3704119A1 (en) 2020-09-09
AU2018361365C1 (en) 2021-08-05
JP2021501768A (ja) 2021-01-21
TW201925199A (zh) 2019-07-01
GEP20227374B (en) 2022-04-25

Similar Documents

Publication Publication Date Title
UY37961A (es) Nuevas y altamente activas indolo-2-carboxamidas sustituidas con pirazolo-pirimidina activas contra el virus de la hepatitis b (vhb)
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
UY38434A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activas contra el virus de la hepatitis b (hbv)
CL2020000487A1 (es) Agentes antivirales contra la hepatitis b.
UY37997A (es) Agentes antivirales contra la hepatitis b
BR112018009009A2 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
GT201300093A (es) Compuestos antivirales
ECSP21031082A (es) Nuevas urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas activas contra el virus de la hepatitis b (hbv)
CO2019009215A2 (es) Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c
UY38436A (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
BR112018069974A2 (pt) compostos de tiazolida para o tratamento de infecções virais
CL2015003358A1 (es) Compuestos derivados de nucleósidos 4'-azido-3'-desoxi-3'-fluoro sustituidos; composición farmacéutica que comprende a dichos compuestos y el uso de los mismos para tratar una infección del virus de la hepatitis c (hcv).
ECSP21079317A (es) Nuevas indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
ECSP21078893A (es) Nuevas fenil y piridil ureas activas contra el virus de la hepatitis b (vhb)
UY38435A (es) Nuevas urea 6,7-dihidro-4h-pirazol[1,5-a] pirazinas activas contra el virus de la hepatitis b (vhb)
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
EA201790776A1 (ru) Комбинированные композиции длительного действия и способы лечения гепатита с
UY38439A (es) Novedosas urea 6,7-dihidro-4h-pirazolo[4,3-c]piridinas activas contra el virus de la hepatitis b (vhb)
ECSP21080338A (es) Nuevas oxalil piperazinas activas contra el virus de la hepatitis b (vhb)
UY38681A (es) Nuevas indolizina-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
TR201910305T4 (tr) Viral enfeksiyonları tedavi etmek için bileşikler.
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114